H. Res. 1099 
In the House of Representatives, U. S., 
September 28, 2018. 
Resolved, That upon the adoption of this resolution the 
House shall be considered to have taken from the Speaker’s 
table the bill, H.R. 6, with the Senate amendment thereto, 
and to have concurred in the Senate amendment with the fol-
lowing amendment: 
In lieu of the matter proposed to be inserted by the 
amendment of the Senate to the text of the bill, insert 
the following: 
SECTION 1. SHORT TITLE; TABLE OF CONTENTS. 
(a) SHORT TITLE.—This Act may be cited as the ‘‘Sub-
stance Use–Disorder Prevention that Promotes Opioid Recov-
ery and Treatment for Patients and Communities Act’’ or the 
‘‘SUPPORT for Patients and Communities Act’’. 
(b) TABLE OF CONTENTS.—The table of contents of this 
Act is as follows: 
Sec. 1. Short title; table of contents. 
TITLE I—MEDICAID PROVISIONS TO ADDRESS THE OPIOID 
CRISIS 
Sec. 1001. At-risk youth Medicaid protection. 
Sec. 1002. Health insurance for former foster youth.
•HRES 1099 EH 
Sec. 1003. Demonstration project to increase substance use provider capacity 
under the Medicaid program. 
Sec. 1004. Medicaid drug review and utilization. 
Sec. 1005. Guidance to improve care for infants with neonatal abstinence syn-
drome and their mothers; GAO study on gaps in Medicaid cov-
erage for pregnant and postpartum women with substance use 
disorder. 
Sec. 1006. Medicaid health homes for substance-use-disorder Medicaid enroll-
ees. 
Sec. 1007. Caring recovery for infants and babies. 
Sec. 1008. Peer support enhancement and evaluation review. 
Sec. 1009. Medicaid substance use disorder treatment via telehealth. 
Sec. 1010. Enhancing patient access to non-opioid treatment options. 
Sec. 1011. Assessing barriers to opioid use disorder treatment. 
Sec. 1012. Help for moms and babies. 
Sec. 1013. Securing flexibility to treat substance use disorders. 
Sec. 1014. MACPAC study and report on MAT utilization controls under State 
Medicaid programs. 
Sec. 1015. Opioid addiction treatment programs enhancement. 
Sec. 1016. Better data sharing to combat the opioid crisis. 
Sec. 1017. Report on innovative State initiatives and strategies to provide hous-
ing-related services and supports to individuals struggling with 
substance use disorders under Medicaid. 
Sec. 1018. Technical assistance and support for innovative State strategies to 
provide housing-related supports under Medicaid. 
TITLE II—MEDICARE PROVISIONS TO ADDRESS THE OPIOID 
CRISIS 
Sec. 2001. Expanding the use of telehealth services for the treatment of opioid 
use disorder and other substance use disorders. 
Sec. 2002. Comprehensive screenings for seniors. 
Sec. 2003. Every prescription conveyed securely. 
Sec. 2004. Requiring prescription drug plan sponsors under Medicare to estab-
lish drug management programs for at-risk beneficiaries. 
Sec. 2005. Medicare coverage of certain services furnished by opioid treatment 
programs. 
Sec. 2006. Encouraging appropriate prescribing under Medicare for victims of 
opioid overdose. 
Sec. 2007. Automatic escalation to external review under a Medicare part D 
drug management program for at-risk beneficiaries. 
Sec. 2008. Suspension of payments by Medicare prescription drug plans and 
MA–PD plans pending investigations of credible allegations of 
fraud by pharmacies. 
TITLE III—FDA AND CONTROLLED SUBSTANCE PROVISIONS 
Subtitle A—FDA Provisions 
CHAPTER 1—IN GENERAL 
Sec. 3001. Clarifying FDA regulation of non-addictive pain products. 
Sec. 3002. Evidence-based opioid analgesic prescribing guidelines and report. 
CHAPTER 2—STOP COUNTERFEIT DRUGS BY REGULATING AND ENHANCING 
ENFORCEMENT NOW
•HRES 1099 EH 
Sec. 3011. Short title. 
Sec. 3012. Notification, nondistribution, and recall of controlled substances. 
Sec. 3013. Single source pattern of imported illegal drugs. 
Sec. 3014. Strengthening FDA and CBP coordination and capacity. 
CHAPTER 3—STOP ILLICIT DRUG IMPORTATION 
Sec. 3021. Short title. 
Sec. 3022. Restricting entrance of illicit drugs. 
CHAPTER 4—SECURING OPIOIDS AND UNUSED NARCOTICS WITH 
DELIBERATE DISPOSAL AND PACKAGING 
Sec. 3031. Short title. 
Sec. 3032. Safety-enhancing packaging and disposal features. 
CHAPTER 5—POSTAPPROVAL STUDY REQUIREMENTS 
Sec. 3041. Clarifying FDA postmarket authorities. 
Subtitle B—Controlled Substance Provisions 
CHAPTER 1—MORE FLEXIBILITY WITH RESPECT TO MEDICATION-ASSISTED 
TREATMENT FOR OPIOID USE DISORDERS 
Sec. 3201. Allowing for more flexibility with respect to medication-assisted 
treatment for opioid use disorders. 
Sec. 3202. Medication-assisted treatment for recovery from substance use dis-
order. 
Sec. 3203. Grants to enhance access to substance use disorder treatment. 
Sec. 3204. Delivery of a controlled substance by a pharmacy to be administered 
by injection or implantation. 
CHAPTER 2—EMPOWERING PHARMACISTS IN THE FIGHT AGAINST OPIOID 
ABUSE 
Sec. 3211. Short title. 
Sec. 3212. Programs and materials for training on certain circumstances under 
which a pharmacist may decline to fill a prescription. 
CHAPTER 3—SAFE DISPOSAL OF UNUSED MEDICATION 
Sec. 3221. Short title. 
Sec. 3222. Disposal of controlled substances of a hospice patient by employees 
of a qualified hospice program. 
Sec. 3223. GAO study and report on hospice safe drug management. 
CHAPTER 4—SPECIAL REGISTRATION FOR TELEMEDICINE CLARIFICATION 
Sec. 3231. Short title. 
Sec. 3232. Regulations relating to a special registration for telemedicine. 
CHAPTER 5—SYNTHETIC ABUSE AND LABELING OF TOXIC SUBSTANCES 
Sec. 3241. Controlled substance analogues. 
CHAPTER 6—ACCESS TO INCREASED DRUG DISPOSAL 
Sec. 3251. Short title. 
Sec. 3252. Definitions.